NewLab Biotechnology (Chengdu) Co., Ltd
About
NewLab Biotechnology has accumulated experience in nearly 400 preclinical translational research projects of innovative pharmaceuticals and medical devices, having helped partners secure over 30 clinical trial approvals in China, 2 in the US, and more than 5 marketing authorizations, while leading or participating in research projects with a total funding scale of tens of millions.
We are also an innovation accelerator specializing in the cardiovascular field, integrating "medical-engineering-R&D + research-production-investment" models, with a proven track record of spearheading the regulatory approval and commercialization of structural heart products including TAVR.
What is your business sector?